Neurocrine Biosciences Inc

Insider buying signals confidence in Neurocrine; Boyer’s 2,096 shares suggest executives expect Phase 2 data to lift stock toward its high.

Neurocrine CFO’s latest share buy signals insider confidence, amid a quiet rally and high social‑media buzz, hinting at a potential Phase‑2 data‑driven surge.

Neurocrine Biosciences insider buy signals confidence; CEO’s 12,830 option exercise reflects bullish outlook amid solid clinical data and low risk‑profile pipeline.

Insider buying at Neurocrine signals confidence in its neuro‑psychiatric pipeline and market‑access strategy, suggesting undervalued upside for investors.